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In the present randomized
phase III trial, we evaluated
the incidence in toxicity of 2
different hypofractionated
radiation therapy regimens.
This preplanned safety
interim analysis has
confirmed that both regimens
are safe and that the study
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https://doi.org/10.1016/j.ijrobp.2017.12.016Purpose: Hypofractionated radiation therapy (HFRT) for localized prostate cancer is
safe and effective. The question that remains is which hypofractionation schedule to
implement. We compared 2 different HFRT regimens in the present study.
Methods and Materials: From June 2013 to July 2016, 160 patients with prostate cancer
were randomly assigned (1:1), within this single-center phase III trial, to 56 Gy (16 frac-
tions of 3.5 Gy; arm A) or 67 Gy (25 fractions of 2.68 Gy; arm B). Randomization was
performed using computer-generated permuted blocks, stratified by previous transurethral
resection of the prostate and the presence of a dominant intraprostatic lesion. Treatment
allocation was not masked, and the clinicians were not blinded. The primary endpoint
was acute gastrointestinal (GI) toxicity, assessed using the Common Terminology Criteria
for Adverse Events, version 4.0, and Radiation Therapy Oncology Group toxicity scale.
An interim analysis of acute toxicity was planned at 160 patients to prove the safety of
both treatment regimens. If 22 of 72 patients had grade 2 GI toxicity, the study arm
would be rejected. The study is registered at ClinicalTrials.gov (NCT01921803).D, PhD, Department of
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Volume 100  Number 4  2018 Toxicity after HFRT for prostate cancer 867Results: In arm A, 20 patients (26%) and 1 patient (1%) developed acute grade 2 and
grade 3 GI toxicity. In arm B, 16 patients (20%) reported acute grade 2 GI toxicity. In
arm A, 42 (55%) and 5 (6%) patients developed acute grade 2 and grade 3 urinary
toxicity. In arm B, 40 (49%) and 7 (9%) patients reported acute grade 2 and grade 3 uri-
nary toxicity. Toxicity peaked during radiation therapy and resolved in the months after
radiation therapy.
Conclusions: With acute grade 2 GI toxicity reported in 21 of 77 patients in arm A and
16 of 82 patients in arm B, both treatment arms can be considered safe.  2017 Elsevier
Inc. All rights reserved.Introduction
Recently, 4 randomized trials comparing conventional-dose
radiation therapy (RT) with hypofractionated RT (HFRT)
demonstrated the noninferiority of HFRT for biochemical
and clinical relapse-free survival for patients with low- and
intermediate-risk prostate cancer (1-4). Although increased
toxicity was reported, the risk of developing toxicity
remained acceptable with HFRT (1-3). Based on the results
of these trials, HFRT can be considered a standard of care
for localized prostate cancer.
With the proven effectiveness of different HFRT
schedules, the side effects will determine which HFRT
schedule to apply. Therefore, we initiated a randomized
phase III study to compare 56 Gy delivered in 4 weeks (arm
A) and 67 Gy delivered in 5 weeks (arm B). An interim
safety analysis was planned to decide whether the study
could be continued. We report the results of the interim
safety analysis, which focused on the incidence of acute
gastrointestinal (GI) and urinary toxicity, and the time
evolution of acute GI and urinary toxicity.
Methods and Materials
The ethics committee of Ghent University Hospital
approved the present single-center, multistage, randomized
phase III study, which has been registered at ClinicalTrials.
gov (ClinicalTrials.gov identifier NCT01921803). A total
of 160 patients were prospectively enrolled from June 2013
to July 2016.
Patients with histologically confirmed stage T1-
T4N0M0 prostate cancer and World Health Organization
performance status of 0 to 2 were eligible. After written
informed consent, the patients were randomized 1:1.
Randomization was performed by computer-generated
permuted blocks with stratification by previous transure-
thral resection of the prostate and the presence of a domi-
nant intraprostatic lesion.
Individuals assigned to arm A received 56 Gy in 16 frac-
tions of 3.5 Gy delivered 4 times weekly. Individuals in arm B
received 67Gy in 25 fractions of2.68Gydaily, 5 timesweekly.
Both regimens were calculated to deliver a normalized iso-
effective dose of 80 Gy (a/b ratio 1.5 Gy) on the prostate.
Before RT, all the patients underwent an abdominopelvicplanning computed tomography scan in the treatment position.
Magnetic resonance imaging of the prostate (consisting of T1-
and T2-weighted imaging and diffusion-weighted imaging)
was performed unless contraindicated.
The clinical target volume (CTV) contained the prostate
and the whole seminal vesicles. The latter were excluded
from the CTV at a normalized isoeffective dose of 50 Gy
when the risk of involvement was <15% (5). The planning
target volume was created using an isotropic 5-mm margin
around the CTV. If a dominant intraprostatic lesion was
found on magnetic resonance imaging, it was delineated
separately and used for the simultaneous integrated boost.
The dose objectives for the targets and organs at risk are
presented in Table E1 (available online at www.redjournal.
org). Planning was performed using intensity modulated RT
with a 7-beam setup. Patient positioning was controlled
using daily cone beam computed tomography.
The primary outcome was GI toxicity occurring during
or within 3 months after HFRT. Toxicity was scored using
Common Terminology Criteria for Adverse Events, version
4.0 (6) and the Radiation Therapy Oncology Group
(RTOG) toxicity scale (7). The secondary endpoints were
acute urinary toxicity, late toxicity (including erectile
dysfunction), quality of life, biochemical control, disease-
free survival, distant metastasis-free survival, prostate
cancer-specific survival, and overall survival.
The study was designed to include 2 stages. For the first
stage, the sample sizewas calculated to rule out an upper limit
of 40% of acute Common Terminology Criteria for Adverse
Events version 4.0/RTOG grade 2 GI complications, with
an expected rate of 25% (derived from our previous study of
HFRT) (8), based on a 1-stage Fleming-A’Hern design. A
power of 83% (a level of 0.038 one-sided) would be obtained
at 72 patients per group. If 22 of the 72 patients developed
acute grade 2 GI complications, the study arm would be
rejected. To allow for a withdrawal rate of 10%, 160 patients
were included in the first stage. The sample size for the sec-
ond stage was calculated analogously to rule out an upper
limit of 35% of patients with grade2 bowel complications,
with an expected rate of 25%. The inclusion of 155 patients
per group would result in a power of 86% (a level of 0.049
one-sided). If 45 of 155 developed acute grade 2 GI
complications, the study arm would be rejected. The sample
size for the first and second stage combined was set at 346,
with a 10% allowance for withdrawal.
Fonteyne et al. International Journal of Radiation Oncology  Biology  Physics868The statistical analysis system (SAS), version 9.4 (SAS
Institute), was used. Differences in toxicity before and after
HFRT were tested using the Friedman test and Wilcoxon
signed rank test (cutoff value for significance, P Z .017).Results
From June 26, 2013 and June 18, 2016, 160 patients were
enrolled in the first stage (Fig. E1; available online at www.
redjournal.org). All but 2 patients received the protocol-
assigned RT dose and schedule. After allocation to arm
A, 1 patient refused participation and received 76 Gy in 38
fractions. Another patient assigned to arm A received the
25-fraction regimen by mistake. Finally, 77 patients
received 16 fractions and 82 patients received 25 fractions.
In arm B, 2 patients died of nonecancer-related cardiac* *
* *
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Fig. 1. Evolution in time of gastrointestinal (GI) toxicity and u
0 to 3 GI toxicity per treatment arm. Data for arm A included toxic
before and 80 patients at 1 and 3 months after hypofractionated
follow-up). (B) Graph showing evolution over time of grade 1 to 3 G
treatment arm. Data for arm A included toxicity for 79 patients at al
at 1 and 3 months after HFRT (2 patients died at 1 month of follow
urinary toxicity. *Statistically significant difference in toxicity scocause at 1 month after HFRT, resulting in 77 and 80 pa-
tients eligible for evaluation per treatment protocol of acute
toxicity at 3 months after HFRT in arms A and B, respec-
tively. The acute toxicity data are presented per treatment
protocol arm. The patient and tumor characteristics before
randomization were equally distributed (Table E2; available
online at www.redjournal.org).GI toxicity
Of the 77 patients evaluated in arm A, 35 (45%), 20 (26%),
and 1 (1%) developed acute grade 1, 2, and 3 GI toxicity,
respectively. Of the 82 patients evaluated in arm B, 46
(56%) and 16 (20%) reported acute grade 1 and 2 GI
toxicity, respectively. No acute grade 3 GI toxicity was
observed in arm B. Severe acute upper GI toxicity was not*
*
*
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rinary toxicity per treatment group. (A) Distribution of grade
ity for 79 patients at all time points and for arm B, 82 patients
radiation therapy (HFRT) (2 patients died at 1 month of
I toxicity. (C) Distribution of grade 0 to 3 urinary toxicity per
l time points and for arm B, 82 patients before and 80 patients
-up). (D) Graph showing evolution over time of grade 1 to 3
res before and after HFRT. Abbreviation: M Z month.
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observed acute grade 2 toxicity.
In both arms, GI toxicity was greatest during and at the
end of HFRT and was significantly increased compared
with the status before HFRT (arm A, P < .0001; arm B,
P < .0001). However, recovery to the status before HFRT
was observed for most patients over time (Fig. 1A and 1B).
Urinary toxicity
In arm A, 22 (29%), 42 (55%), and 5 (6%) patients
developed acute grade 1, 2, and 3 urinary toxicity,
respectively. In arm B, 31 (38%), 40 (49%), and 7 (9%)
patients reported acute grade 1, 2, and 3 urinary toxicity,
respectively. Retention, nocturia, and pollakisuria were the
most frequently observed acute grade 2 urinary toxicities,
reported by >30% of patients in both arms. Similar to rectal
toxicity, urinary toxicity was greatest during and at the
end of HFRT (arm A, P < .0001; arm B, P < .0001; Fig. 1C
and 1D).
Discussion
Our study results have confirmed that the incidence of acute
grade 3 GI toxicity is extremely low. The incidence of acute
grade 2 GI toxicity in arm B was in line with the toxicity re-
ported in the Conventional or Hypofractionated High Dose
Intensity Modulated Radiotherapy in Prostate Cancer trial andTable 1 Overview of acute toxicity reported in different randomize
Variable
Dearnaley
et al (1) Lee et al (3) Ca
Schedule 20  3 Gy 28  2.5 Gy
Scoring system LENT/SOMA supplemented
with RMH scoring system
and RTOG
CTCAE,
version 3.0
Time point 4 wk 18 wk Maximum
toxicity 90 d
after EBRT
W
GI toxicity (%)
Grade 1 68* 22* 32
Grade 2 27* 3 10
Grade 3 0 0 1
Grade 4 0 0 1
Urinary
toxicity (%)
Grade 1 80* 25* 35
Grade 2 32* 5 24
Grade 3 4* 0 3
Grade 4 0 0 0
Abbreviations: CTCAE Z Common Terminology Criteria for Adverse Ev
Organization for Research and Treatment of Cancer; GI Z gastrointestinal; L
agement, analytic; RMH Z Royal Marsden Hospital; RTOG Z Radiation The
* Data derived from Figure 1 and represent grade 1, 2, and 3 toxicity.compared favorably with the incidence of GI toxicity of the
HYPRO (hypofractionated irradiation for prostate cancer) trial
(Table 1) (1, 9). The greater incidence of acute grade 2 GI
toxicity in arm A might add to the evidence that multiple
fractions of >3.4 Gy/d is associated with a greater risk of
developing acute GI toxicity (9).
Our results regarding acute grade 3 urinary toxicity were
also in line with the results reported in the CHHiP, PROFIT
(prostate fractionated irradiation trial), and RTOG trials,
and the incidence remained far below the 20% incidence
observed in the HYPRO study (1-3, 9). In contrast, our
incidence of acute grade 2 urinary toxicity was substan-
tially greater (Table 1) (1-3, 9). This can be explained by
the w20% of our patients who had grade 2 urinary
symptoms before HFRT. Baseline toxicity is a significant
predictor for both GI and urinary toxicity (10).
Nevertheless, HFRT-induced toxicity appears to be
temporary. For both treatment arms, we found a clear peak
incidence in acute bowel and urinary toxicity during RT
that resolved in the months after RT. A similar pattern has
been described in the CHHiP trial (11).
We acknowledge that, owing to the small sample size,
small changes in toxicity could have been missed. Another
limitation of the present study was that it was a single-
center study. Reporting on acute toxicity is important,
because it is a significant predictive factor for the devel-
opment of late toxicity (8). Longer follow-up is required to
evaluate whether our applied HFRT regimens are safe and
effective in the long term.d hypofractionation trials compared with our acute toxicity data
tton et al (2)
Aluwini
et al (8)
Present study
Arm A Arm B
20  3 Gy 19  3.4 Gy 16  3.5 Gy 25  2.68 Gy
RTOG RTOG, EORTC CTCAE, version 4.0
orst grade
of toxicity
during first
14 wk
Maximum toxicity
within 3 months
after EBRT
Maximum toxicity
3 mo after EBRT
43 32 43 56
16 36 29 20
1 6 1 0
0 0 0 0
45 30 29 38
27 40 55 49
4 20 6 9
0 1 0 0
ents; EBRT Z external beam radiation therapy; EORTC Z European
ENT/SOMA Z late effects on normal tissue/subjective, objective, man-
rapy Oncology Group.
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The present interim analysis of acute toxicity after 2 HFRT
schedules for prostate cancer has demonstrated the safety of
both regimens. Nevertheless, the incidence of GI and uri-
nary toxicity was not negligible and warrants further
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